Jørn Carlsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jørn Carlsen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
M. Iversen
3 shared publicationsC.B. Andersen
2 shared publicationsHenrik Arendrup
Department of Cardiothoracic Surgery, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2 shared publicationsJan Aldershvile
Medical Department B, Division of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 shared publicationsSvend Aage Mortensen
Medical Department B, Division of Cardiology, Rigshospitalet, Copehagen University Hospital, Copenhagen, Denmark
2 shared publicationsSøren Boesgaard
2 shared publications
Latest Publications
- 1 April 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (4) , S490
Cardiovascular Magnetic Resonance Imaging for Risk Assessment and Prediction of Clinical Worsening in Pulmonary Arterial Hypertension
- 1 April 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (4) , S490
Cardiovascular Magnetic Resonance Imaging for Risk Assessment and Prediction of Clinical Worsening in Pulmonary Arterial Hypertension
- 8 July 2014
- Vol. 31 (2) , 149-53
Recurrence of sarcoid granulomas in lung transplant recipients is common and does not affect overall survival.
Sarcoidosis represents 2,5% of all indications for lung transplantation and criteria are generally assumed to be the same as for pulmonary fibrosis. Recurrence of granulomas in transplanted lungs has earlier been proved to derive from recipient immune cells, but its role in relation to lung function and overall survival after lung transplantation remains uncertain. To identify recurrent granuloma in transbronchial biopsies in patients receiving lung transplant because of sarcoidosis, and relate the findings to overall survival and lung function. A total of 620 patients were transplanted at this centre from 1992 until august 2012. This study comprised all patients (n=25) transplanted due to pulmonary sarcoidosis. Lung functions, trans-bronchial biopsies, and survival were compared in patients with and without recurrence of granulomas. Granulomas were defined as non-necrotizing epitheloid granulomas with multinucleated giant cells according to standard criteria (formation of epitheloid giant cells) without presence of infection. Approximately 30% of lung transplant recipients due to sarcoidosis have recurrence of sarcoid granulomas. Recurrence of granulomas does not affect overall survival or lung function.
- 8 July 2014
- Vol. 31 (2) , 149-53
Recurrence of sarcoid granulomas in lung transplant recipients is common and does not affect overall survival.
Sarcoidosis represents 2,5% of all indications for lung transplantation and criteria are generally assumed to be the same as for pulmonary fibrosis. Recurrence of granulomas in transplanted lungs has earlier been proved to derive from recipient immune cells, but its role in relation to lung function and overall survival after lung transplantation remains uncertain. To identify recurrent granuloma in transbronchial biopsies in patients receiving lung transplant because of sarcoidosis, and relate the findings to overall survival and lung function. A total of 620 patients were transplanted at this centre from 1992 until august 2012. This study comprised all patients (n=25) transplanted due to pulmonary sarcoidosis. Lung functions, trans-bronchial biopsies, and survival were compared in patients with and without recurrence of granulomas. Granulomas were defined as non-necrotizing epitheloid granulomas with multinucleated giant cells according to standard criteria (formation of epitheloid giant cells) without presence of infection. Approximately 30% of lung transplant recipients due to sarcoidosis have recurrence of sarcoid granulomas. Recurrence of granulomas does not affect overall survival or lung function.
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e87-e88
Successful pregnancy and delivery in a patient with vasoreactive idiopathic pulmonary arterial hypertension
- 1 March 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 172 (1) , e87-e88
Successful pregnancy and delivery in a patient with vasoreactive idiopathic pulmonary arterial hypertension
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P301
Pulmonary venous hypertension in end-stage chronic obstructive pulmonary disease with preserved systolic left ventricular function
Purpose: Pulmonary venous hypertension (PVH) in heart failure with preserved left ventricular ejection fraction (HFpEF) is an established comorbidity in chronic obstructive pulmonary disease (COPD). PVH is characterized by mean pulmonary artery pressure (mPAP) ≥25mmHg and pulmonary capillary wedge pressure (PCWP) >15mmHg. The transpulmonary gradient (TPG=mPAP-PCWP) can distinguish between passive/congestive and reactive/mixed hemodynamic profiles, and could potentially have prognostic implications in COPD. Methods: This retrospective analysis identified patients with PVH using right heart catheterization (RHC) from a consecutive cohort of 409 patients being evaluated for lung transplantation due to end-stage COPD at our institution during 1991-2010. In addition, cardiac function was assessed by 2-D and Doppler echocardiography, multigated radionuclide angiography and coronary angiography. Patients with PVH were compared to a previously described population with pulmonary hypertension (PH; mPAP ≥25mmHg, PCWP 12mmHg as reactive/mixed). Survival analysis was conducted by means of Kaplan-Meier analysis and log-rank test. Results: Fifty-two patients (13%) fulfilled the criteria for PVH. All patients were in NYHA functional class III-IV with forced expiratory volume in the first second (FEV1) 23±7% and total lung capacity (TLC) 118±21%. None of the patients had systolic left heart failure. One hundred and forty-six patients (36%) had PH and served as a control group. PVH patients presented with higher mPAP, right atrial mean pressure and lower pulmonary vascular resistance (PVR). Twenty-seven patients with PVH (52%) had a reactive/mixed hemodynamic profile with a post-and a pre-capillary component, while the remaining 25 patients (48%) had a passive/congestive hemodynamic profile characterized by an isolated post-capillary contribution to PVH. Patients with reactive/mixed hemodynamic profiles had higher systolic, diastolic and mean pulmonary artery pressure with a higher PVR. Subdividing the PVH group according to TPG revealed an inferior prognosis for patients with TPG >12 mmHg compared to a TPG ≤12 mmHg (p=0.024). Conclusions: PVH with HFpEF is a frequent finding in end-stage COPD (13%). The prognosis in PVH is comparable to that of PH. However, reactive/mixed forms of PVH characterized by generally higher pulmonary pressures are associated with worse outcome than PVH patients with passive/congestive hemodynamic profiles.
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , P301
Pulmonary venous hypertension in end-stage chronic obstructive pulmonary disease with preserved systolic left ventricular function
Purpose: Pulmonary venous hypertension (PVH) in heart failure with preserved left ventricular ejection fraction (HFpEF) is an established comorbidity in chronic obstructive pulmonary disease (COPD). PVH is characterized by mean pulmonary artery pressure (mPAP) ≥25mmHg and pulmonary capillary wedge pressure (PCWP) >15mmHg. The transpulmonary gradient (TPG=mPAP-PCWP) can distinguish between passive/congestive and reactive/mixed hemodynamic profiles, and could potentially have prognostic implications in COPD. Methods: This retrospective analysis identified patients with PVH using right heart catheterization (RHC) from a consecutive cohort of 409 patients being evaluated for lung transplantation due to end-stage COPD at our institution during 1991-2010. In addition, cardiac function was assessed by 2-D and Doppler echocardiography, multigated radionuclide angiography and coronary angiography. Patients with PVH were compared to a previously described population with pulmonary hypertension (PH; mPAP ≥25mmHg, PCWP 12mmHg as reactive/mixed). Survival analysis was conducted by means of Kaplan-Meier analysis and log-rank test. Results: Fifty-two patients (13%) fulfilled the criteria for PVH. All patients were in NYHA functional class III-IV with forced expiratory volume in the first second (FEV1) 23±7% and total lung capacity (TLC) 118±21%. None of the patients had systolic left heart failure. One hundred and forty-six patients (36%) had PH and served as a control group. PVH patients presented with higher mPAP, right atrial mean pressure and lower pulmonary vascular resistance (PVR). Twenty-seven patients with PVH (52%) had a reactive/mixed hemodynamic profile with a post-and a pre-capillary component, while the remaining 25 patients (48%) had a passive/congestive hemodynamic profile characterized by an isolated post-capillary contribution to PVH. Patients with reactive/mixed hemodynamic profiles had higher systolic, diastolic and mean pulmonary artery pressure with a higher PVR. Subdividing the PVH group according to TPG revealed an inferior prognosis for patients with TPG >12 mmHg compared to a TPG ≤12 mmHg (p=0.024). Conclusions: PVH with HFpEF is a frequent finding in end-stage COPD (13%). The prognosis in PVH is comparable to that of PH. However, reactive/mixed forms of PVH characterized by generally higher pulmonary pressures are associated with worse outcome than PVH patients with passive/congestive hemodynamic profiles.
- 29 February 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (2) , S90-90
86: Analysis of Risk Factors for the Development of Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation
- 29 February 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (2) , S90-90
86: Analysis of Risk Factors for the Development of Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation
- 31 March 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (3) , 296-302
Induction therapy after cardiac transplantation: A comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection
- 31 March 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (3) , 296-302
Induction therapy after cardiac transplantation: A comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection
- 1 January 2004
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 23 (1) , 80-87
Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease
- 1 January 2004
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 23 (1) , 80-87
Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease